Overview

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men

Status:
Recruiting

Trial end date:
2022-06-22

Target enrollment:

Participant gender:

Summary

This is a blinded and placebo-controlled study of topical testosterone replacement therapy (TRT) in symptomatic hypogonadal men with increased risk for cardiovascular (CV) disease.

Phase:

Phase 4

Details

Lead Sponsor:

AbbVie

Collaborators:

AbbVie; Acerus Pharmaceuticals Corporation/ Aytu Biosciences Inc.; Allergan Sales LLC; Endo Pharmaceuticals; Upsher-Smith Laboratories LLC
Acerus Pharmaceuticals Corporation/ Aytu Biosciences Inc.
Allergan Sales, LLC
Endo Pharmaceuticals
Upsher-Smith Laboratories LLC

Treatments:

Methyltestosterone
Testosterone
Testosterone 17 beta-cypionate
Testosterone enanthate
Testosterone undecanoate